Agreement on Most-Favored-Nation Pricing for American Patients

On September 30, 2025, President Donald J. Trump announced an agreement with Pfizer aimed at implementing most-favored-nation (MFN) pricing for American patients. This agreement enables State Medicaid programs to access MFN drug prices on Pfizer products, promising significant savings for millions of patients. Additionally, it addresses the issue of foreign nations benefiting from lower drug prices while Americans face higher costs, ensuring that innovative medicines are fairly priced in the U.S. market.

The MFN pricing initiative aims to provide American patients with tangible cost savings on essential medications. Under this agreement, several popular drugs will be offered at substantial discounts. For example, medications like Eucrisa, Xeljanz, and Zavzpret will be available at discounts of up to 80%, allowing patients to access treatments at more affordable prices.

This policy follows President Trump’s Executive Order from May 2025, which sought to align U.S. drug prices with those in other developed countries. The announcement emphasizes the administration’s commitment to reducing prescription costs for Americans and addressing the longstanding disparity in drug pricing across countries. By ensuring that pharmaceutical companies repatriate increased foreign revenue and offer deeper discounts domestically, the administration aims to prioritize the healthcare needs of American patients.

Original: article